

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace, without prejudice, all prior versions, and listings, of claims in the application.

1. -20. (cancelled)

21. (currently amended) A method for the treatment of anemia in a patient, which comprises administering to said patient a combination of a Gas6 compound and ~~erythropoeitin~~ erythropoietin, either simultaneously or sequentially, thereby ensuring a synergistic rescue effect on ~~erythropoeisis~~ erythropoiesis in said patient, wherein said ~~erythropoeitin~~ erythropoietin is selected from the group consisting of:

- ~~a naturally occurring wild type erythropoeitin~~ erythropoietin,
- ~~a glycosylation variant of erythropoeitin~~
- epoetin,
- darbepoetin,
- erythropoietin having a modified N-linked glycosylation pattern,
- ~~a point mutation or~~ erythropoietin with a point mutation in the helices or interhelical regions of the four alpha helical bundle motif, wherein said erythropoietin with a point mutation stimulates the production of red blood cells,
- or
- a deletion mutant of erythropoeitin erythropoietin in the helices or interhelical regions of the four alpha helical bundle motif, which retains stimulation of wherein said deletion mutant of erythropoietin stimulates the production of red blood cells and,
- a physiologically tolerated salt of said ~~naturally occurring wild type~~

~~erythropoietin~~ erythropoietin, said epoetin, said darbepoetin, glycosylation variant said erythropoietin having a modified N-linked glycosylation pattern, said erythropoietin with a point ~~mutant~~ mutation, or and said deletion mutant of erythropoietin;

and wherein said Gas6 compound is selected from the group consisting of:

- wild type Gas6,
- a fragment of Gas6 lacking the A domain or,
- a fragment of Gas6 consisting essentially of the D domain,
- a Gas6 mutant having at least 95% sequence identity at the amino acid level ~~said Gas6 fragment~~ compared to the wild type Gas6 protein and retaining the function of activating the Gas6 receptors Axl, Mer and Sky, and,
- a physiologically tolerated salt of said wild type Gas6, said Gas 6 fragment lacking the A domain, said Gas6 fragment consisting essentially of the D domain, or and said Gas6 mutant.

22.-27. (cancelled)

28. (withdrawn) The method according to claim 21, wherein said DNA encoding a Gas6 compound is comprised in a vector.
29. (withdrawn) The method according to claim 21, wherein said DNA encoding a Gas6 compound is engineered into a cell.
30. (previously presented) The method of claim 21, wherein said anemia is caused by or associated with a disorder selected from the group consisting of chronic renal failure, aplastic anemia, hemolytic anemia, malignancy, an endocrine deficiency or is the

result of chemotherapy.

31. (cancelled)
32. (previously presented) The method according to claim 21, wherein said anemia is caused by chronic renal failure.